Protect the Science, Build the Brand: Seven IP Lessons for Beauty, Wellness and Clinic Founders

Walk into any longevity startup and ask the founder about their intellectual property. You'll get one of two reactions, and both are tells.

The first is the flinch: the founder who treats IP as an intimidating, expensive, lawyer-shaped obstacle standing between them and the actual work of science. They'll get to it later. After the next study. After the round. It's a cost centre, a compliance box, a hurdle to clear when forced.

The second is the swagger, the founder who waves a single-filed patent like a talisman and believes the war is won. We're protected, they say, as if a patent number were a force field. They've confused having a document with having a defence.

Here's what neither camp understands, and what investors understood a long time ago: IP is not a hurdle, and it is not a shield. It's a strategy or it's nothing. And a venture capitalist deciding whether to fund you is not evaluating your patent. They're evaluating whether your patent, your brand, your data, and your commercial plan tell a single coherent story about why you'll still own this market in five years.

Most founders are telling three disconnected stories. That's the problem.

VCs aren't buying your breakthrough. They're buying the file.

There's a fantasy at the heart of the science-led startup: that a good enough discovery sells itself. That if the mechanism is real and the data is clean, capital is a formality.

It isn't, and the reason is unglamorous. By the time a serious investor is in diligence, they assume the science works, or they wouldn't be in the room. What they're now trying to figure out is whether the science is bankable. Whether it integrates with a defensible commercial position. Whether the thing you discovered can be owned, protected, scaled, and sold without a larger company walking in and taking it.

That's why a standalone patent application impresses no one who's serious. A patent in isolation answers exactly one question: did you file something, and ignores every question that actually decides the deal: Does it cover what you sell? Can you operate without infringing someone else? Who actually owns it? Does your brand create value the patent can't? Is your data defensible enough that the patent means anything?

The hard question for every founder:

When an investor opens your data room, do they find a strategy — or do they find a patent sitting next to a pitch deck, with no connective tissue between them?

Because the gap between those two is where valuations get cut in half.

What's actually patentable and the trap of patenting the wrong thing

Let's puncture the most expensive misconception in beauty and longevity: that natural ingredients can't be protected, so why bother.

You generally can't patent a molecule that nature already made. An NAD+ precursor, spermidine, a peptide, a marine extract, an adaptogen — if it exists in nature, owning the compound itself is largely off the table, and founders who build their moat there are building on sand. The supplement world already has its monument to this mistake: a celebrated NAD+ precursor whose patents were drawn around an isolated, naturally occurring vitamin, only to be invalidated as a product of nature. Strong science. Big market. Worthless claims.

But "you can't patent the molecule" is not the same as "you can't patent anything." What's genuinely protectable is almost always the system around the ingredient — the delivery mechanism, the specific formulation and ratios, the manufacturing method, a bioavailability improvement, the diagnostic that proves the effect, the protocol. You don't patent the vitamin. You patent the thing that makes your vitamin work better than everyone else's.

Which means the real question isn't can I patent this, it's am I patenting the thing that actually creates my advantage, drawn tightly enough to survive a challenge? A broad, vague patent feels safe and protects nothing. A narrow, precise one feels modest and holds. Founders consistently choose the feeling of safety over the fact of it.

The trade-secret decision almost no one makes on purpose

Here's a question that separates strategic founders from the rest: 

Should you even file a patent at all?

A patent is a bargain, and founders forget its second half. In exchange for roughly twenty years of protection, you publish your invention to the entire world. You teach every competitor exactly how you did it, in writing, forever and the moment the patent expires, it's a free recipe for anyone who wants it.

Sometimes that bargain is worth it. Sometimes it's a catastrophe.

The most valuable formula in the history of consumer goods was never patented. The world's best-known soft drink has been kept as a trade secret for over a century, precisely because patenting it would have meant publishing it and then losing exclusivity after 20 years. As a secret, it can last forever.

The deciding question is brutally practical: can a competent competitor reverse-engineer this from the finished product? If yes, if someone can tear apart your device or analyse your formulation and reconstruct it, then a patent is your friend, because they'll learn how you did it anyway and at least the patent lets you sue them. But if your edge lives in something invisible from the outside, a fermentation condition, a manufacturing nuance, a process that leaves no fingerprint in the final product, then publishing it in a patent is insane. You'd be handing competitors a map to something they could never otherwise find.

So the founder who reflexively files patents on everything is not being thorough. They may be systematically disclosing their best secrets to the world in exchange for protection they don't even need.

Have you ever decided, deliberately, what to patent and what to lock in a vault or have you just been filing because that's what founders are told to do?

Brand and community are real assets. They are also a target.

Now the part the beauty world wants to be true, and the part it needs to hear.

It's genuinely correct that a company's brand identity, community, and digital presence are often as valuable as the underlying science. A trusted brand commands pricing power, lowers acquisition cost, and builds a moat of loyalty that no competitor can copy overnight. In a category drowning in unproven claims, trust itself is defensible. This is real value, and investors increasingly know how to price it.

But there's a lethal failure mode hiding within that truth, and it's worth saying plainly: brand and community are assets only when they sit atop defensible technology. On their own, they're a flare in the night sky telling better-capitalised competitors exactly where the demand is.

The wearables world wrote this lesson in blood. Two companies, two bets. One quietly built its patents around how the hardware was actually constructed. The other built community, software, beautiful branding, a devoted following. When the fight came, the brand-and-community player was ordered out of the world’s largest market, while the patent holder kept selling. The movement didn't save them. Nothing copies as easily as a vibe once someone owns the thing underneath it.

So the integration question is the one that matters:

Does your brand sit on a foundation you own or are you building a beautiful house on land that belongs to whoever files first?

The boring failures that kill deals before the science is ever discussed

Here is where most science-led founders lose, and it has nothing to do with science.

Investors call it diligence; founders should call it the reckoning. Three quiet questions end more deals than any failed experiment.

Who actually invented this, and who owns it? Was it the founder? The university the founder spun out of, which may still hold rights nobody renegotiated? A contractor who wrote the algorithm on a vague agreement? A formulation partner who did the real work on a handshake? Deals collapse not because the IP is weak but because the chain of title is a mess and nobody can prove, on paper, who owns what. It is the most preventable failure in the entire process, and it is everywhere.

Is your data actually defensible? A clinical result is only as good as the rigour behind it: the protocol, the controls, the sample size, the lab notebooks, the documented methodology a sophisticated investor's technical advisor will pick apart. "We saw a strong effect" is a marketing claim. Validated, reproducible, properly documented data is an asset. Founders routinely confuse the two, and the data room is where that confusion gets exposed.

Can you even sell this? Freedom to operate, not "do you have a patent," but can you ship this product without being sued by someone whose patent you've never read? Owning your own improvement and having the right to operate are completely different things, and you can hold the former while infringing the latter the day you launch.

None of these is a science question. All of them assume your science is good. And all of them get answered "no" or "we're not sure" by founders who spent five years on the biology and five minutes on the file.

The disclosure trap: how founders narrate away their own value

One more, because it's the cruellest, and because it implicates everyone who builds platforms for founders, including this one.

Founders need visibility. So they post the breakthrough on social. They pitch it publicly. They publish the paper. They share the deck. Attention is oxygen.

And in much of the world, public disclosure before filing permanently destroys patentability. The United States offers some grace. Europe largely does not. China largely does not. The reveal meant to build momentum can instead hand your invention to everyone, for free, forever, right before you try to protect it.

The premature white paper, the eager conference talk, the founder who "builds in public" because that's what the playbook says, these aren't marketing wins. For a defensible invention, they can be acts of self-destruction.

Have you filed before you talk or are you about to give the most valuable thing you own to a room full of strangers and competitors, and call it thought leadership?

Investor readiness is one story, told four ways

Strip it all back and the thesis is simple. Investors don't fund science, patents, brands, or data. They fund the integration of all four into a single, coherent argument for why you'll still own this in five years.

The patent that protects what you actually sell. The trade secret you chose to keep rather than publish. The brand that sits on owned ground instead of borrowed demand. The data clean enough to survive an expert tearing into it. The ownership chain that proves, on paper, that it's all yours.

Most founders have these as four separate conversations with four separate people, stitched together the week before diligence. The ones who got funded built them as a single strategy from the start because they understood that IP was never the lawyers' problem to handle later. It was the spine the whole company hangs from.

So the only question that matters, the one to ask yourself before any investor asks it for you: when someone opens the file, do your science, your brand, your data, and your ownership all tell the same story?

Or are you hoping nobody reads closely?

To continue the conversation, join INNOCOS events, where beauty, wellness and longevity leaders explore the intersection of science, brand building, investment and commercialisation. Visit innocosevents.com to discover upcoming programs and request an invitation.

This article provides general business information and does not constitute legal advice. Patentability, freedom to operate, data rights and disclosure rules depend on the facts and relevant jurisdictions. Seek advice from appropriately qualified professionals.